{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:09:56Z","timestamp":1773371396383,"version":"3.50.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.07444.BD"],"award-info":[{"award-number":["2020.07444.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-PAT\/0959\/2021"],"award-info":[{"award-number":["PTDC\/MED-PAT\/0959\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-PAT\/0959\/2021"],"award-info":[{"award-number":["PTDC\/MED-PAT\/0959\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2023.03111.BD"],"award-info":[{"award-number":["2023.03111.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UI\/BD\/153607\/2022"],"award-info":[{"award-number":["UI\/BD\/153607\/2022"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-PAT\/0959\/2021"],"award-info":[{"award-number":["PTDC\/MED-PAT\/0959\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-PAT\/0959\/2021"],"award-info":[{"award-number":["PTDC\/MED-PAT\/0959\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-PAT\/0959\/2021"],"award-info":[{"award-number":["PTDC\/MED-PAT\/0959\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transthyretin (TTR) has gained attention due to its implication in Alzheimer\u2019s Disease (AD) by modulating amyloid-beta (A\u03b2) pathology. This study aimed to establish associations between TTR and key AD biomarkers, to enhance our understanding of the role of TTR in AD pathogenesis. We evaluated TTR levels and tetrameric instability in plasma and CSF in mild cognitive impairment (MCI-AD) and Dementia-AD patients examining associations with clinical, biochemical and genetic data. Plasma TTR levels were lower in Dementia-AD, especially in women. In the MCI-AD group, CSF TTR levels inversely correlated with markers of amyloid pathology and neurodegeneration such as A\u03b240, p-Tau181, t-Tau and NfL. CSF TTR instability was negatively associated with CSF A\u03b242, indicating an association with increased amyloid burden. In the whole cohort, plasma TTR instability correlated with CSF TTR instability. In line with the strong association between CSF TTR instability and A\u03b242, we showed increased TTR instability in samples incubated with A\u03b242. No significant associations were observed in the Dementia-AD group. This study emphasizes that TTR is associated with A\u03b2 clearance and neurodegeneration. We propose A\u03b242 and its increase in the brain as a factor destabilizing the TTR tetrameric fold, impairing TTR function.<\/jats:p>","DOI":"10.1038\/s41598-026-41717-7","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:16:01Z","timestamp":1773332161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levels and instability of transthyretin and correlations with core biomarkers in Alzheimer\u2019s disease"],"prefix":"10.1038","author":[{"given":"Tiago","family":"Gi\u00e3o","sequence":"first","affiliation":[]},{"given":"Miguel","family":"T\u00e1buas-Pereira","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Baldeiras","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Saavedra","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Saraiva","sequence":"additional","affiliation":[]},{"given":"Maria Ros\u00e1rio","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Santana","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Cardoso","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"41717_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jalz.2016.09.015","volume":"13","author":"WD Brenowitz","year":"2017","unstructured":"Brenowitz, W. D. et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement. 13, 654\u2013662. https:\/\/doi.org\/10.1016\/j.jalz.2016.09.015 (2017).","journal-title":"Alzheimers Dement."},{"key":"41717_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi, A., DeCarli, C. & Schneider, J. A. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 134, 171\u2013186. https:\/\/doi.org\/10.1007\/s00401-017-1717-7 (2017).","journal-title":"Acta Neuropathol."},{"key":"41717_CR3","first-page":"afac173","volume":"51","author":"W Bai","year":"2022","unstructured":"Bai, W. et al. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing. 51, afac173 (2022).","journal-title":"Age Ageing"},{"key":"41717_CR4","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ana.26927","volume":"95","author":"A Ghanem","year":"2024","unstructured":"Ghanem, A. et al. Prevalence of and annual conversion rates to mild cognitive impairment and dementia: Prospective, longitudinal study of an essential tremor cohort. Ann. Neurol. 95, 1193\u20131204. https:\/\/doi.org\/10.1002\/ana.26927 (2024).","journal-title":"Ann. Neurol."},{"key":"41717_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen, R. C. et al. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 56, 303\u2013308. https:\/\/doi.org\/10.1001\/archneur.56.3.303 (1999).","journal-title":"Arch. Neurol."},{"key":"41717_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/archneurol.2009.106","volume":"66","author":"ST Farias","year":"2009","unstructured":"Farias, S. T. et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch. Neurol. 66, 1151\u20131157. https:\/\/doi.org\/10.1001\/archneurol.2009.106 (2009).","journal-title":"Arch. Neurol."},{"key":"41717_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/s1041610204000092","volume":"16","author":"M Bruscoli","year":"2004","unstructured":"Bruscoli, M. & Lovestone, S. Is MCI really just early dementia? A systematic review of conversion studies. Int. Psychogeriatr. 16, 129\u2013140. https:\/\/doi.org\/10.1017\/s1041610204000092 (2004).","journal-title":"Int. Psychogeriatr."},{"key":"41717_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/DNND.S228939","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen, J. & Langerman, H. Alzheimer\u2019s disease - Why we need early diagnosis. Degener. Neurol. Neuromuscul. Dis. 9, 123\u2013130. https:\/\/doi.org\/10.2147\/DNND.S228939 (2019).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"41717_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jalz.2009.01.028","volume":"5","author":"DL Weimer","year":"2009","unstructured":"Weimer, D. L. & Sager, M. A. Early identification and treatment of Alzheimer\u2019s disease: Social and fiscal outcomes. Alzheimer\u2019s & Dementia 5, 215\u2013226. https:\/\/doi.org\/10.1016\/j.jalz.2009.01.028 (2009).","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"41717_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2019.100005","volume":"1","author":"R Khoury","year":"2019","unstructured":"Khoury, R. & Ghossoub, E. Diagnostic biomarkers of Alzheimer\u2019s disease: A state-of-the-art review. Biomark. Neuropsychiatry 1, 100005. https:\/\/doi.org\/10.1016\/j.bionps.2019.100005 (2019).","journal-title":"Biomark. Neuropsychiatry"},{"key":"41717_CR11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240\u20131249. https:\/\/doi.org\/10.1212\/WNL.0000000000001991 (2015).","journal-title":"Neurology"},{"key":"41717_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100056","volume":"12","author":"M Sch\u00f6ll","year":"2025","unstructured":"Sch\u00f6ll, M. et al. Cutting through the noise: A narrative review of Alzheimer\u2019s disease plasma biomarkers for routine clinical use. J. Prev. Alzheimers Dis. 12, 100056. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100056 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"41717_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062075","author":"T Gi\u00e3o","year":"2020","unstructured":"Gi\u00e3o, T. et al. Undiscovered roles for Transthyretin: From a transporter protein to a new therapeutic target for Alzheimer\u2019s Disease. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21062075 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"41717_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0305-0491(94)00229-N","volume":"111","author":"AR Aldred","year":"1995","unstructured":"Aldred, A. R., Brack, C. M. & Schreiber, G. The cerebral expression of plasma protein genes in different species. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 111, 1\u201315. https:\/\/doi.org\/10.1016\/0305-0491(94)00229-N (1995).","journal-title":"Comp. Biochem. Physiol. B. Biochem. Mol. Biol."},{"key":"41717_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/prca.200780040","volume":"2","author":"S Roche","year":"2008","unstructured":"Roche, S., Gabelle, A. & Lehmann, S. Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. Proteom. Clin. Appl. 2, 428\u2013436. https:\/\/doi.org\/10.1002\/prca.200780040 (2008).","journal-title":"Proteom. Clin. Appl."},{"key":"41717_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1096\/fj.05-4106fje","volume":"20","author":"AF Nunes","year":"2006","unstructured":"Nunes, A. F., Saraiva, M. J. & Sousa, M. M. Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J. 20, 166\u2013168. https:\/\/doi.org\/10.1096\/fj.05-4106fje (2006).","journal-title":"FASEB J."},{"key":"41717_CR17","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.febslet.2013.03.011","volume":"587","author":"M Vieira","year":"2013","unstructured":"Vieira, M. & Saraiva, M. J. Transthyretin regulates hippocampal 14-3-3\u03b6 protein levels.. FEBS Lett. 587, 1482\u20131488. https:\/\/doi.org\/10.1016\/j.febslet.2013.03.011 (2013).","journal-title":"FEBS Lett."},{"key":"41717_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.neurobiolaging.2007.04.007","volume":"29","author":"J Brouillette","year":"2008","unstructured":"Brouillette, J. & Quirion, R. Transthyretin: A key gene involved in the maintenance of memory capacities during aging. Neurobiol. Aging 29, 1721\u20131732. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.04.007 (2008).","journal-title":"Neurobiol. Aging"},{"key":"41717_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nlm.2007.07.006","volume":"88","author":"JC Sousa","year":"2007","unstructured":"Sousa, J. C. et al. Transthyretin influences spatial reference memory.. Neurobiol. Learn. Mem. 88, 381\u2013385. https:\/\/doi.org\/10.1016\/j.nlm.2007.07.006 (2007).","journal-title":"Neurobiol. Learn. Mem."},{"key":"41717_CR20","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1073\/pnas.91.18.8368","volume":"91","author":"A Schwarzman","year":"1994","unstructured":"Schwarzman, A. et al. Transthyretin sequesters A\u03b2 protein and prevents amyloid formation. Proc. Natl. Acad. Sci. 91, 8368\u20138372. https:\/\/doi.org\/10.1073\/pnas.91.18.8368 (1994).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"41717_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.febslet.2008.02.034","volume":"582","author":"GA Costa","year":"2008","unstructured":"Costa, G. A., Saraiva, M. J. & Cardoso, I. Transthyretin binding to ABeta peptide - Impact on A-Beta fibrillogenesis and toxicity.. FEBS Lett. 582, 936\u2013942. https:\/\/doi.org\/10.1016\/j.febslet.2008.02.034 (2008).","journal-title":"FEBS Lett."},{"key":"41717_CR22","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1021\/acs.jmedchem.9b01970","volume":"63","author":"EY Cotrina","year":"2020","unstructured":"Cotrina, E. Y. et al. Calorimetric studies of binary and ternary molecular interactions between transthyretin, A\u03b2 peptides, and small-molecule chaperones toward an alternative strategy for Alzheimer\u2019s Disease drug discovery.. J. Med. Chem. 63, 3205\u20133214. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01970 (2020).","journal-title":"J. Med. Chem."},{"key":"41717_CR23","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1021\/bi101280t","volume":"49","author":"J Du","year":"2010","unstructured":"Du, J. & Murphy, R. M. Characterization of the interaction of \u03b2-amyloid with transthyretin monomers and tetramers. Biochemistry 49, 8276\u20138289. https:\/\/doi.org\/10.1021\/bi101280t (2010).","journal-title":"Biochemistry"},{"key":"41717_CR24","doi-asserted-by":"publisher","first-page":"19423","DOI":"10.1523\/JNEUROSCI.2561-13.2013","volume":"33","author":"X Li","year":"2013","unstructured":"Li, X. et al. Mechanisms of transthyretin inhibition of \u03b2-amyloid aggregation in vitro.. J. Neurosci. 33, 19423\u201319433. https:\/\/doi.org\/10.1523\/JNEUROSCI.2561-13.2013 (2013).","journal-title":"J. Neurosci."},{"key":"41717_CR25","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.jmb.2018.06.005","volume":"430","author":"L Nilsson","year":"2018","unstructured":"Nilsson, L. et al. Transthyretin interferes with A\u03b2 amyloid formation by redirecting oligomeric nuclei into non-amyloid aggregates. J. Mol. Biol. 430, 2722\u20132733. https:\/\/doi.org\/10.1016\/j.jmb.2018.06.005 (2018).","journal-title":"J. Mol. Biol."},{"key":"41717_CR26","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.bbadis.2013.09.011","volume":"1832","author":"R Cascella","year":"2013","unstructured":"Cascella, R. et al. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1832, 2302\u20132314. https:\/\/doi.org\/10.1016\/j.bbadis.2013.09.011 (2013).","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"41717_CR27","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1523\/JNEUROSCI.1919-07.2007","volume":"27","author":"SH Choi","year":"2007","unstructured":"Choi, S. H. et al. Accelerated A\u03b2 deposition in APPswe\/PS1\u2206E9 mice with hemizygous deletions of TTR (transthyretin). J. Neurosci. 27, 7006\u20137010. https:\/\/doi.org\/10.1523\/JNEUROSCI.1919-07.2007 (2007).","journal-title":"J. Neurosci."},{"key":"41717_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3233\/JAD-2011-110488","volume":"27","author":"SM Oliveira","year":"2011","unstructured":"Oliveira, S. M., Ribeiro, C. A., Cardoso, I. & Saraiva, M. J. Gender-dependent transthyretin modulation of brain Amyloid-\u03b2 levels: Evidence from a mouse model of Alzheimer\u2019s disease. J. Alzheimers Dis. 27, 429\u2013439. https:\/\/doi.org\/10.3233\/JAD-2011-110488 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"41717_CR29","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1073\/pnas.0712197105","volume":"105","author":"JN Buxbaum","year":"2008","unstructured":"Buxbaum, J. N. et al. Transthyretin protects Alzheimer\u2019s mice from the behavioral and biochemical effects of A\u03b2 toxicity. Proc. Natl. Acad. Sci. U. S. A. 105, 2681\u20132686. https:\/\/doi.org\/10.1073\/pnas.0712197105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"41717_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep20164","author":"M Alemi","year":"2016","unstructured":"Alemi, M. et al. Transthyretin participates in beta-amyloid transport from the brain to the liver- Involvement of the Low-density lipoprotein receptor-related protein 1?. Sci. Rep. https:\/\/doi.org\/10.1038\/srep20164 (2016).","journal-title":"Sci. Rep."},{"key":"41717_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00883-8","author":"T Gi\u00e3o","year":"2021","unstructured":"Gi\u00e3o, T. et al. Neuroprotection in early stages of Alzheimer\u2019s disease is promoted by transthyretin angiogenic properties. Alzheimers Res. Ther. https:\/\/doi.org\/10.1186\/s13195-021-00883-8 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"41717_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1600-0404.1986.tb07863.x","volume":"74","author":"I Elovaara","year":"1986","unstructured":"Elovaara, I., Maury, C. P. J. & Palo, J. Serum amysoid A protein, albumin and prealbumin in Alzheimer\u2019s disease and in demented patients with Down\u2019s syndrome. Acta Neurol. Scand. 74, 245\u2013250. https:\/\/doi.org\/10.1111\/j.1600-0404.1986.tb07863.x (1986).","journal-title":"Acta Neurol. Scand."},{"key":"41717_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JAD-2011-110611","volume":"28","author":"L Velayudhan","year":"2012","unstructured":"Velayudhan, L. et al. Plasma transthyretin as a candidate marker for Alzheimer\u2019s disease. J. Alzheimers Dis. 28, 369\u2013375. https:\/\/doi.org\/10.3233\/JAD-2011-110611 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"41717_CR34","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2174\/156720512803251057","volume":"9","author":"SI Ribeiro","year":"2012","unstructured":"Ribeiro, S. I. et al. Transthyretin decrease in plasma of MCI and AD patients: Investigation of mechanisms for disease modulation,. Curr. Alzheimer Res. 9, 881\u2013889. https:\/\/doi.org\/10.2174\/156720512803251057 (2012).","journal-title":"Curr. Alzheimer Res."},{"key":"41717_CR35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1432-1033.1997.00662.x","volume":"249","author":"I Longo Alves","year":"1997","unstructured":"Longo Alves, I., Hays, M. T. & Saraiva, M. J. M. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur. J. Biochem. 249, 662\u2013668. https:\/\/doi.org\/10.1111\/j.1432-1033.1997.00662.x (1997).","journal-title":"Eur. J. Biochem."},{"key":"41717_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045368","author":"MJ Ribeiro, Saraiva","year":"2012","unstructured":"Ribeiro, Saraiva, M. J. & Cardoso, I. -Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A\u03b2 Peptide - Relevance in Alzheimer\u2019s Disease. PLoS One https:\/\/doi.org\/10.1371\/journal.pone.0045368 (2012).","journal-title":"PLoS One"},{"key":"41717_CR37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/cns.12707","volume":"23","author":"M Alemi","year":"2017","unstructured":"Alemi, M., Silva, S. C., Santana, I. & Cardoso, I. Transthyretin stability is critical in assisting beta amyloid clearance\u2013 Relevance of transthyretin stabilization in Alzheimer\u2019s disease. CNS Neurosci. Ther. 23, 605\u2013619. https:\/\/doi.org\/10.1111\/cns.12707 (2017).","journal-title":"CNS Neurosci. Ther."},{"key":"41717_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 270\u2013279. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008 (2011).","journal-title":"Alzheimers Dement."},{"key":"41717_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005 (2011).","journal-title":"Alzheimers Dement."},{"key":"41717_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0362-2","volume":"10","author":"I Baldeiras","year":"2018","unstructured":"Baldeiras, I. et al. Addition of the A\u03b242\/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer\u2019s disease dementia in mild cognitive impairment. Alzheimers Res. Ther. 10, 33. https:\/\/doi.org\/10.1186\/s13195-018-0362-2 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"41717_CR41","doi-asserted-by":"publisher","first-page":"S647","DOI":"10.3233\/JAD-179908","volume":"64","author":"I Santana","year":"2018","unstructured":"Santana, I. et al. Underlying biological processes in mild cognitive impairment: Amyloidosis versus neurodegeneration. J. Alzheimers Dis. 64, S647\u2013S657. https:\/\/doi.org\/10.3233\/JAD-179908 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"41717_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"41717_CR43","first-page":"27","volume-title":"Escalas e Testes na Dem\u00eancia","author":"M Guerreiro","year":"2003","unstructured":"Guerreiro, M., Silva, A. & Botelho, M. Avalia\u00e7\u00e3o Breve do Estado Mental. In Escalas e Testes na Dem\u00eancia (ed. Grupo de Estudos de Envelhecimento Cerebral e Dem\u00eancia) 27\u201332 (Novartis, 2003)."},{"key":"41717_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"41717_CR45","volume-title":"Montreal cognitive assessment (MoCA): vers\u00e3o final portuguesa","author":"MR Sim\u00f5es","year":"2008","unstructured":"Sim\u00f5es, M. R. Montreal cognitive assessment (MoCA): vers\u00e3o final portuguesa (Servi\u00e7o Avalia\u00e7\u00e3o Psicol\u00f3gica, Fac Psicol e Ci\u00eancias da Educ da Univ Coimbra, 2008)."},{"key":"41717_CR46","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer\u2019s disease. Am. J. Psychiatry 141, 1356\u20131364. https:\/\/doi.org\/10.1176\/ajp.141.11.1356 (1984).","journal-title":"Am. J. Psychiatry"},{"key":"41717_CR47","first-page":"448","volume":"19","author":"RC Mohs","year":"1983","unstructured":"Mohs, R. C., Rosen, W. G. & Davis, K. L. The Alzheimer\u2019s disease assessment scale: An instrument for assessing treatment efficacy. Psychopharmacol. Bull. 19, 448\u2013450 (1983).","journal-title":"Psychopharmacol. Bull."},{"key":"41717_CR48","first-page":"33","volume-title":"Escalas e Testes na Dem\u00eancia","author":"M Guerreiro","year":"2003","unstructured":"Guerreiro, M., Fonseca, S. & Barreto, J. Escala de Avalia\u00e7\u00e3o da Doen\u00e7a de Alzheimer. In Escalas e Testes na Dem\u00eancia (ed. Grupo de Estudos de Envelhecimento Cerebral e Dem\u00eancia) 33\u201349 (Novartis, 2003)."},{"key":"41717_CR49","unstructured":"Guerreiro, M. Contribution of neuropsychology for the study of dementia (PhD Thesis). Fac Med Lisbon (1998)."},{"key":"41717_CR50","first-page":"637","volume":"24","author":"L Berg","year":"1988","unstructured":"Berg, L. Clinical dementia rating (CDR). Psychopharmacol. Bull. 24, 637\u2013639 (1988).","journal-title":"Psychopharmacol. Bull."},{"key":"41717_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5014\/ajot.53.5.471","volume":"53","author":"I G\u00e9linas","year":"1999","unstructured":"G\u00e9linas, I., Gauthier, L., McIntyre, M. & Gauthier, S. Development of a functional measure for persons with Alzheimer\u2019s disease: The disability assessment for dementia. Am. J. Occup. Ther. 53, 471\u2013481. https:\/\/doi.org\/10.5014\/ajot.53.5.471 (1999).","journal-title":"Am. J. Occup. Ther."},{"key":"41717_CR52","first-page":"107","volume-title":"Escalas e Testes na Dem\u00eancia","author":"O Leit\u00e3o","year":"2008","unstructured":"Leit\u00e3o, O. Avalia\u00e7\u00e3o da Incapacidade Funcional na Dem\u00eancia. In Escalas e Testes na Dem\u00eancia (ed. Grupo de Estudos de Envelhecimento Cerebral e Dem\u00eancia) 107\u2013110 (Novartis, 2008)."},{"key":"41717_CR53","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/wnl.48.5_suppl_6.10s","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings, J. L. The neuropsychiatric inventory: Assessing psychopathology in dementia patients. Neurology 48, S10-6. https:\/\/doi.org\/10.1212\/wnl.48.5_suppl_6.10s (1997).","journal-title":"Neurology"},{"key":"41717_CR54","first-page":"67","volume-title":"Escalas e Testes na Dem\u00eancia","author":"O Leit\u00e3o","year":"2003","unstructured":"Leit\u00e3o, O. & Nina, A. Invent\u00e1rio Neuropsiqui\u00e1trico. In Escalas e Testes na Dem\u00eancia (ed. Grupo de Estudos de Envelhecimento Cerebral e Dem\u00eancia) 67\u201386 (Novartis, 2003)."},{"key":"41717_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 126\u2013135. https:\/\/doi.org\/10.1212\/WNL.0000000000004826 (2018).","journal-title":"Neurology"},{"key":"41717_CR56","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13803395.2011.589374","volume":"33","author":"S Freitas","year":"2011","unstructured":"Freitas, S., Sim\u00f5es, M. R., Alves, L. & Santana, I. Montreal cognitive assessment (MoCA): Normative study for the Portuguese population. J. Clin. Exp. Neuropsychol. 33, 989\u2013996. https:\/\/doi.org\/10.1080\/13803395.2011.589374 (2011).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"41717_CR57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n, G. C. et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250\u2013260 (1993).","journal-title":"Neurology"},{"key":"41717_CR58","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M del Campo","year":"2012","unstructured":"del Campo, M. et al. Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: An update. Biomark. Med. 6, 419\u2013430. https:\/\/doi.org\/10.2217\/bmm.12.46 (2012).","journal-title":"Biomark. Med."},{"key":"41717_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0165-0270(94)90168-6","volume":"53","author":"R Crook","year":"1994","unstructured":"Crook, R., Hardy, J. & Duff, K. Single-day apolipoprotein E genotyping. J. Neurosci. Methods 53, 125\u2013127. https:\/\/doi.org\/10.1016\/0165-0270(94)90168-6 (1994).","journal-title":"J. Neurosci. Methods"},{"key":"41717_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leit\u00e3o","year":"2019","unstructured":"Leit\u00e3o, M. J. et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimers Res. Ther. 11, 91. https:\/\/doi.org\/10.1186\/s13195-019-0550-8 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"41717_CR61","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson, N. et al. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7, 386-395.e6. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2243 (2011).","journal-title":"Alzheimers Dement."},{"key":"41717_CR62","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CRJ Jack","year":"2018","unstructured":"Jack, C. R. J. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"key":"41717_CR63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ene.15058","volume":"29","author":"A Silva-Sp\u00ednola","year":"2022","unstructured":"Silva-Sp\u00ednola, A. et al. Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. Eur. J. Neurol. 29, 36\u201346. https:\/\/doi.org\/10.1111\/ene.15058 (2022).","journal-title":"Eur. J. Neurol."},{"key":"41717_CR64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jcmm.12024","volume":"17","author":"AC Teixeira","year":"2013","unstructured":"Teixeira, A. C. & Saraiva, M. J. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: An escape from ERAD. J. Cell. Mol. Med. 17, 429\u2013435. https:\/\/doi.org\/10.1111\/jcmm.12024 (2013).","journal-title":"J. Cell. Mol. Med."},{"key":"41717_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13506129.2019.1583193","volume":"26","author":"F Bezerra","year":"2019","unstructured":"Bezerra, F. et al. Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous. Amyloid 26, 73\u201374. https:\/\/doi.org\/10.1080\/13506129.2019.1583193 (2019).","journal-title":"Amyloid"},{"key":"41717_CR66","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.dadm.2015.04.003","volume":"1","author":"K Uchida","year":"2015","unstructured":"Uchida, K. et al. Amyloid-\u03b2 sequester proteins as blood-based biomarkers of cognitive decline. Alzheimer\u2019s Dement (Amsterdam, Netherlands) 1, 270\u2013280. https:\/\/doi.org\/10.1016\/j.dadm.2015.04.003 (2015).","journal-title":"Alzheimer\u2019s Dement (Amsterdam, Netherlands)"},{"key":"41717_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55318-0","volume":"9","author":"Y-T Tien","year":"2019","unstructured":"Tien, Y.-T. et al. Plasma transthyretin as a predictor of amnestic mild cognitive impairment conversion to dementia. Sci. Rep. 9, 18691. https:\/\/doi.org\/10.1038\/s41598-019-55318-0 (2019).","journal-title":"Sci. Rep."},{"key":"41717_CR68","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/JAD-2011-102145","volume":"25","author":"SH Han","year":"2011","unstructured":"Han, S. H. et al. Human serum transthyretin levels correlate inversely with Alzheimer\u2019s disease. J. Alzheimers Dis. 25, 77\u201384. https:\/\/doi.org\/10.3233\/JAD-2011-102145 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"41717_CR69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11010-008-9841-2","volume":"317","author":"I Gon\u00e7alves","year":"2008","unstructured":"Gon\u00e7alves, I. et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol. Cell. Biochem. 317, 137\u2013142. https:\/\/doi.org\/10.1007\/s11010-008-9841-2 (2008).","journal-title":"Mol. Cell. Biochem."},{"key":"41717_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10571-008-9339-1","volume":"29","author":"T Quintela","year":"2009","unstructured":"Quintela, T. et al. 17\u03b2-Estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway. Cell. Mol. Neurobiol. 29, 475\u2013483. https:\/\/doi.org\/10.1007\/s10571-008-9339-1 (2009).","journal-title":"Cell. Mol. Neurobiol."},{"key":"41717_CR71","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/WNL.54.4.833","volume":"54","author":"JJ Manly","year":"2000","unstructured":"Manly, J. J. et al. Endogenous estrogen levels and Alzheimer\u2019s disease among postmenopausal women. Neurology 54, 833\u2013837. https:\/\/doi.org\/10.1212\/WNL.54.4.833 (2000).","journal-title":"Neurology"},{"key":"41717_CR72","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.neuroscience.2010.05.031","volume":"169","author":"Z Amtul","year":"2010","unstructured":"Amtul, Z., Wang, L., Westaway, D. & Rozmahel, R. F. Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer\u2019s disease. Neuroscience 169, 781\u2013786. https:\/\/doi.org\/10.1016\/j.neuroscience.2010.05.031 (2010).","journal-title":"Neuroscience"},{"key":"41717_CR73","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/prca.201600009","volume":"10","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer\u2019s disease, mild cognitive impairment, and healthy individuals. Proteomics Clin. Appl. 10, 1225\u20131241. https:\/\/doi.org\/10.1002\/prca.201600009 (2016).","journal-title":"Proteomics Clin. Appl."},{"key":"41717_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-2008-14102","volume":"14","author":"SF Gloeckner","year":"2008","unstructured":"Gloeckner, S. F. et al. Quantitative analysis of transthyretin, tau and amyloid-\u03b2 in patients with dementia. J. Alzheimers Dis. 14, 17\u201325. https:\/\/doi.org\/10.3233\/JAD-2008-14102 (2008).","journal-title":"J. Alzheimers Dis."},{"key":"41717_CR75","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/jnnp.63.4.506","volume":"63","author":"JM Serot","year":"1997","unstructured":"Serot, J. M., Christmann, D., Dubost, T. & Couturier, M. Cerebrospinal fluid Transthyretin: Aging and late onset Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 63, 506\u2013508. https:\/\/doi.org\/10.1136\/jnnp.63.4.506 (1997).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"41717_CR76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0014-5793(98)00234-8","volume":"425","author":"A Merched","year":"1998","unstructured":"Merched, A. et al. Apolipoprotein E, Transthyretin and actin in the CSF of Alzheimer\u2019s patients: Relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett. 425, 225\u2013228. https:\/\/doi.org\/10.1016\/S0014-5793(98)00234-8 (1998).","journal-title":"FEBS Lett."},{"key":"41717_CR77","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JAD-2009-0966","volume":"16","author":"SF Hansson","year":"2009","unstructured":"Hansson, S. F. et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer\u2019s disease patients. J. Alzheimers Dis. 16, 389\u2013397. https:\/\/doi.org\/10.3233\/JAD-2009-0966 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"41717_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-9-22","volume":"9","author":"KR Wildsmith","year":"2014","unstructured":"Wildsmith, K. R. et al. Identification of longitudinally dynamic biomarkers in Alzheimer\u2019s disease cerebrospinal fluid by targeted proteomics. Mol. Neurodegener. 9, 22. https:\/\/doi.org\/10.1186\/1750-1326-9-22 (2014).","journal-title":"Mol. Neurodegener."},{"key":"41717_CR79","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/13547500903108423","volume":"14","author":"AE Roher","year":"2009","unstructured":"Roher, A. E. et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer\u2019s disease. Biomarkers 14, 493\u2013501. https:\/\/doi.org\/10.3109\/13547500903108423 (2009).","journal-title":"Biomarkers"},{"key":"41717_CR80","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1468-1331.2009.02841.x","volume":"17","author":"K Schultz","year":"2010","unstructured":"Schultz, K. et al. Transthyretin as a potential CSF biomarker for Alzheimer\u2019s disease and dementia with Lewy bodies: Effects of treatment with cholinesterase inhibitors. Eur. J. Neurol. 17, 456\u2013460. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02841.x (2010).","journal-title":"Eur. J. Neurol."},{"key":"41717_CR81","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1021\/acs.biochem.8b00517","volume":"57","author":"P Mangrolia","year":"2018","unstructured":"Mangrolia, P. & Murphy, R. M. Retinol-binding protein interferes with Transthyretin-mediated \u03b2-Amyloid aggregation inhibition. Biochemistry 57, 5029\u20135040. https:\/\/doi.org\/10.1021\/acs.biochem.8b00517 (2018).","journal-title":"Biochemistry"},{"key":"41717_CR82","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","volume":"86","author":"LF Maia","year":"2015","unstructured":"Maia, L. F. et al. CNS involvement in V30M Transthyretin amyloidosis: Clinical, neuropathological and biochemical findings. J. Neurol. Neurosurg. Psychiatry. 86, 159\u2013167. https:\/\/doi.org\/10.1136\/jnnp-2014-308107 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"41717_CR83","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00007890-200107270-00023","volume":"72","author":"H Terazaki","year":"2001","unstructured":"Terazaki, H. et al. Variant Transthyretin in blood circulation can transverse the blood-cerebrospinal barrier: Qualitative analyses of Transthyretin metabolism in sequential liver transplantation. Transplantation 72, 296\u2013299. https:\/\/doi.org\/10.1097\/00007890-200107270-00023 (2001).","journal-title":"Transplantation"},{"key":"41717_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020224","author":"T Gi\u00e3o","year":"2022","unstructured":"Gi\u00e3o, T., Teixeira, T., Almeida, M. R. & Cardoso, I. Choroid plexus in Alzheimer\u2019s Disease\u2014The current state of knowledge. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines10020224 (2022).","journal-title":"Biomedicines"},{"key":"41717_CR85","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1073\/pnas.87.17.6589","volume":"87","author":"RH Costa","year":"1990","unstructured":"Costa, R. H. et al. Similarities in Transthyretin gene expression and differences in transcription factors: Liver and yolk sac compared to choroid plexus. Proc. Natl. Acad. Sci. U. S. A. 87, 6589\u20136593. https:\/\/doi.org\/10.1073\/pnas.87.17.6589 (1990).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"41717_CR86","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1016\/S0021-9258(17)35671-5","volume":"261","author":"PW Dickson","year":"1986","unstructured":"Dickson, P. W. et al. Rat choroid plexus specializes in the synthesis and the secretion of Transthyretin (prealbumin). Regulation of Transthyretin synthesis in choroid plexus is independent from that in liver. J. Biol. Chem. 261, 3475\u20133478 (1986).","journal-title":"J. Biol. Chem."},{"key":"41717_CR87","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1111\/j.1742-4658.2010.07802.x","volume":"277","author":"Z Wang","year":"2010","unstructured":"Wang, Z. & Burke, P. A. Hepatocyte nuclear factor-4\u03b1 interacts with other hepatocyte nuclear factors in regulating Transthyretin gene expression. FEBS J. 277, 4066\u20134075. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07802.x (2010).","journal-title":"FEBS J."},{"key":"41717_CR88","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1523\/JNEUROSCI.2417-11.2011","volume":"31","author":"X Li","year":"2011","unstructured":"Li, X., Masliah, E., Reixach, N. & Buxbaum, J. Neuronal production of Transthyretin in human and murine Alzheimer\u2019s disease: Is it protective?. J. Neurosci. 31, 12483\u201312490. https:\/\/doi.org\/10.1523\/JNEUROSCI.2417-11.2011 (2011).","journal-title":"J. Neurosci."},{"key":"41717_CR89","first-page":"41","volume":"107","author":"T Shirahama","year":"1982","unstructured":"Shirahama, T. et al. Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Am. J. Pathol. 107, 41\u201350 (1982).","journal-title":"Am. J. Pathol."},{"key":"41717_CR90","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1523\/JNEUROSCI.2211-04.2004","volume":"24","author":"TD Stein","year":"2004","unstructured":"Stein, T. D. et al. Neutralization of Transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSw mice resulting in Tau phosphorylation and loss of hippocampal neurons: Support for the Amyloid Hypothesis. J. Neurosci. 24, 7707\u20137717. https:\/\/doi.org\/10.1523\/JNEUROSCI.2211-04.2004 (2004).","journal-title":"J. Neurosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41717-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:16:07Z","timestamp":1773332167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41717-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":90,"alternative-id":["41717"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41717-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present research complied with the ethical guidelines for human experimentation stated in the Declaration of Helsinki and was approved by the Ethics Board of Coimbra University Hospital (OBS.SF.088.2022) and Committee for Ethical and Responsible Conduct of Research of i3S (N 16\/CECRI\/2023). All subjects or responsible caregivers, whichever appropriate, gave their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Uploaded to a preprint server (https:\/\/www.biorxiv.org\/): https:\/\/www.biorxiv.org\/content\/10.1101\/2025.01.24.634710v1","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Preprint"}}]}}